Interchem double liability company (Odesa) is designing three new molecules, Interchem Head Anatoliy Reder has said.

"Interchem is designing three new molecules. Now the preclinical phase for the medicine to treat sore throat has been finished. We're working on a nootropic medicine that will restore memory: the results of preclinical trials are encouraging," he said in an interview with Interfax-Ukraine.

Reder also said that Interchem is registering a medicine under the bioequivalence scheme for the first time. Two preparations of a drug, usually a generic and the original patented drug, are assessed.

"I hope that by the end of this year the preparation will be registered using the bioequivalence scheme. Today European standards require confirmation of bioequivalence of generics when they study the amount of preparations in organism," he said.

"If a Ukrainian company wants to enter any foreign market, even the Eastern African market, it has to have a bioequivalence file and, of course, a GMP-certified production site. In many countries bioequivalence is the main barrier during the registration [of medicines]," Reder said.